

Clas MalmestrÃm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8366939/publications.pdf>

Version: 2024-02-01

46
papers

2,829
citations

218381

26
h-index

214527

47
g-index

47
all docs

47
docs citations

47
times ranked

4027
citing authors

#	ARTICLE	IF	CITATIONS
1	Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. <i>Neurology</i> , 2017, 89, 2230-2237.	1.5	307
2	Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. <i>Annals of Neurology</i> , 2011, 69, 83-89.	2.8	295
3	Rituximab in multiple sclerosis. <i>Neurology</i> , 2016, 87, 2074-2081.	1.5	278
4	Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. <i>Annals of Neurology</i> , 2016, 79, 950-958.	2.8	190
5	Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis. <i>Journal of Neurology</i> , 2011, 258, 882-888.	1.8	131
6	Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. <i>Journal of Neurochemistry</i> , 2017, 141, 296-304.	2.1	124
7	Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. <i>Lancet Neurology</i> , The, 2011, 10, 691-701.	4.9	114
8	Inflammation-related plasma and CSF biomarkers for multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 12952-12960.	3.3	102
9	Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 43-50.	1.4	101
10	Acyclovir Levels in Serum and Cerebrospinal Fluid after Oral Administration of Valacyclovir. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 2438-2441.	1.4	90
11	Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 62-71.	1.4	81
12	MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS). <i>BMC Immunology</i> , 2013, 14, 32.	0.9	80
13	Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2013, 128, e33-e36.	1.0	77
14	Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1587-1595.	1.4	73
15	Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. <i>Multiple Sclerosis Journal</i> , 2013, 19, 765-774.	1.4	66
16	YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2016, 292, 52-57.	1.1	64
17	Relapses in multiple sclerosis are associated with increased CD8+ T-cell mediated cytotoxicity in CSF. <i>Journal of Neuroimmunology</i> , 2008, 196, 159-165.	1.1	57
18	Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 448-454.	1.4	55

#	ARTICLE	IF	CITATIONS
19	CSF levels of YKL-40 are increased in MS and decrease with immunosuppressive treatment. <i>Journal of Neuroimmunology</i> , 2014, 269, 87-89.	1.1	51
20	An observational study of alemtuzumab following fingolimod for multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e320.	3.1	51
21	IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: Implications for their possible immunopathogenic roles. <i>Journal of Neuroimmunology</i> , 2006, 175, 176-182.	1.1	50
22	Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis. <i>European Journal of Neurology</i> , 2016, 23, 796-806.	1.7	46
23	Cerebrospinal fluid biomarkers of β -amyloid metabolism in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 543-552.	1.4	43
24	Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers. <i>PLoS ONE</i> , 2018, 13, e0194828.	1.1	32
25	The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2013, 264, 100-105.	1.1	30
26	Extreme Stability of Chitotriosidase in Cerebrospinal Fluid makes it a Suitable Marker for Microglial Activation in Clinical Trials. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 273-276.	1.2	26
27	Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: an observational study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 189-194.	0.9	25
28	Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2015, 358, 201-206.	0.3	22
29	High Interferon- γ Uniquely in γ T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2017, 8, 260.	2.2	19
30	Serum levels of LIGHT in MS. <i>Multiple Sclerosis Journal</i> , 2013, 19, 871-876.	1.4	17
31	Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies. <i>Journal of Neuroimmunology</i> , 2017, 306, 25-30.	1.1	17
32	SARS-CoV-2 a trigger of myelin oligodendrocyte glycoprotein-associated disorder. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 1296-1301.	1.7	16
33	First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS. <i>Journal of Neurology</i> , 2014, 261, 2016-2018.	1.8	14
34	Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive MS from relapsing-remitting MS. <i>Journal of Neurochemistry</i> , 2018, 146, 322-332.	2.1	14
35	Ultrasensitive DNA Immune Repertoire Sequencing Using Unique Molecular Identifiers. <i>Clinical Chemistry</i> , 2020, 66, 1228-1237.	1.5	10
36	MS risk genes are transcriptionally regulated in CSF leukocytes at relapse. <i>Multiple Sclerosis Journal</i> , 2013, 19, 403-410.	1.4	9

#	ARTICLE	IF	CITATIONS
37	Neuronal antibodies in adult patients with new-onset seizures: A prospective study. <i>Brain and Behavior</i> , 2019, 9, e01442.	1.0	8
38	Upper Respiratory Infections and MRI Activity in Relapsing-Remitting Multiple Sclerosis. <i>Neuroepidemiology</i> , 2015, 45, 83-89.	1.1	7
39	CSF orexin-A levels after rituximab treatment in recent onset narcolepsy type 1. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	3.1	7
40	Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies. <i>Acta Neurologica Scandinavica</i> , 2019, 139, 422-427.	1.0	6
41	Cerebrospinal fluid CD4 ⁺ /CD8 ⁺ ratio in diagnosing neurosarcoidosis. <i>Acta Neurologica Scandinavica</i> , 2020, 142, 480-485.	1.0	6
42	Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis. <i>Scientific Reports</i> , 2019, 9, 17309.	1.6	5
43	Processing in prefrontal cortex underlies tactile direction discrimination: An fMRI study of a patient with a traumatic spinal cord lesion. <i>Neuroscience Letters</i> , 2010, 483, 197-200.	1.0	4
44	A Sensitive Method for Detecting Peptide-specific CD4 ⁺ T Cell Responses in Peripheral Blood from Patients with Myasthenia Gravis. <i>Frontiers in Immunology</i> , 2017, 8, 1370.	2.2	2
45	Intrathecal immunoreactivity in people with or without previous infectious mononucleosis. <i>Acta Neurologica Scandinavica</i> , 2020, 142, 161-168.	1.0	2
46	Persons with suspicious onset of multiple sclerosis but with undetermined diagnosis had persistent lower cognition and reduced quality of life. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 102977.	0.9	2